NCT05999604View on ClinicalTrials.gov

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Multiple Sclerosis
Interventions
DRUG

Ocrelizumab Injection [Ocrevus]

Semestrial administration

DRUG

Ocrelizumab Injection [Ocrevus]

Annual administration

Trial Locations (1)

75019

RECRUITING

Fondation Adolphe de Rothschild, Paris

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK